Year: 2026
Type: article
Abstract: Chronic pain affects more than 20% of adults but is often refractory to the current arsenal of approved analgesics, thus necessitating the development of new strategies. In an interesting article published in the current issue of Molecular Therapy Nucleic Acids,1 Shin and colleagues describe the analgesic effects of a virally delivered peptide that targets Cav3.2 calcium channel activity.
Authors: Maria A. Gandini, Gerald W. Zamponi
Institutions: University of Calgary, Hotchkiss Brain Institute
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W7235717880
